Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03154476 · ClinicalTrials.gov registry record · Phase 3
Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study
A Phase 3 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT03154476: Completed Phase 3 study, sponsored by Mayo Clinic.
NCT03154476 is a Phase 3 study that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03154476, a Phase 3 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the medication, sildenafil (also known as Revatio), can slow or stop the progression of liver disease in patients who previously had a Fontan operation.
Interventions
- DRUG Placebo
- DRUG Sildenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-07-05 |
| Est. Completion | 2019-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03154476
The ClinicalTrials.gov registry entry for NCT03154476 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03154476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03154476 about?
NCT03154476 is a clinical study titled "Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study". The purpose of this study is to determine if the medication, sildenafil (also known as Revatio), can slow or stop the progression of liver disease in patients who previously had a Fontan operation.
What is the current status of trial NCT03154476?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2017-07-05. Estimated completion is 2019-06-30.
What interventions are being tested in trial NCT03154476?
The interventions under investigation include: Placebo (DRUG), Sildenafil (DRUG).
Who is sponsoring clinical trial NCT03154476?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.